2-TUR QANDLI DIABETI MAVJUD BEMORLARDA SURUNKALI BUYRAKLAR KASALLIGINING KECHISHIGA 2-TUR NATRIY SIMPORTYOR GLYUKOZA INGIBITORLARI(SGLT2) TA'SIRINING TAQQOSLAMA TAHLILI.
Keywords:
2-tur qandli diabeti mavjud bemorlarda surunkali buyraklar kasalligining kechishiga 2-tur natriy simportyor glyukoza ingibitorlari(SGLT2) ta'sirini taqqoslama tahlil qilish. Bemorlarda dapa- va empagliflozinlar ta'sirini o'zaro solishtirish. Preparatlarning natijasini klinik va laborator tekshirish va baholash.Abstract
Bemorlarda o'tkazilgan laborator tekshiruvlar natijasida Forsiga qabul qilgan 14 ta bemorda surunkali buyraklar kasalligining xavfi absolyut kamayishi (ARR) kuzatilgan. Koptokchalar filtratsiya tezligi(eGFR) 3-bosqichdan 70-80ml/daq gacha ortgan. Albuminuriya esa 1000mg/g gacha pasaygan (ОР 0,79 (95% ДИ: 0,72, 0,87) va makroalbuminuriyani regressiyasiga sabab bo'lgani kuzatildi (ОР 1,82 (95% ДИ: 1,51, 2,20). Dapagliflozinning samarali ta'siri boshlang'ichga nisbatan xavf nisbati (Hazard Ratio)HR 0,64 (95% ДИ(Ishonchlilik indeksi): 0,52–0,79) и HR 0,50 (95% ДИ: 0,35–0,72) bo'lgan. Qo'shimcha ravishda bemorlarda nojo'ya ta'sirlar sifatida dizuriya, poliuriya,ba'zan nikturiya kuzatilgan.
References
1.Nespoux J, Vallon V. Renal effects of SGLT2 inhibitors: an update. Curr Opin Nephrol Hypertens. 2020;
2.Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct 8;383(15)
3.Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-617.
4.Wheeler DC, Stefansson BV, Batiushin M, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. 2020.
5.Инструкция по медицинскому применению лекарственного препарата Форсига® (таблетки, покрытые пленочной оболочкой, 5 мг, 10 мг). Регистрационное удостоверение № ЛП 002596 от 21.08.2014.
